Legacy Capital Group California Inc. Has $1.46 Million Stake in CVS Health Corporation $CVS

Legacy Capital Group California Inc. lifted its holdings in CVS Health Corporation (NYSE:CVS) by 37.4% during the first quarter, HoldingsChannel.com reports. The firm owned 20,260 shares of the pharmacy operator’s stock after purchasing an additional 5,510 shares during the period. Legacy Capital Group California Inc.’s holdings in CVS Health were worth $1,455,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently modified their holdings of the company. Swiss RE Ltd. bought a new stake in shares of CVS Health during the 4th quarter worth about $26,000. Sankala Group LLC acquired a new position in CVS Health during the fourth quarter worth about $28,000. Caitong International Asset Management Co. Ltd lifted its stake in shares of CVS Health by 407.2% in the 3rd quarter. Caitong International Asset Management Co. Ltd now owns 350 shares of the pharmacy operator’s stock valued at $26,000 after acquiring an additional 281 shares during the last quarter. Mcguire Capital Advisors Inc. acquired a new stake in CVS Health during the 4th quarter worth approximately $28,000. Finally, Ares Financial Consulting LLC bought a new stake in shares of CVS Health in the 4th quarter valued at about $29,000. Institutional investors own 80.66% of the company’s stock.

Insider Transactions at CVS Health

In other news, EVP Tilak Mandadi sold 69,551 shares of the stock in a transaction on Friday, May 8th. The stock was sold at an average price of $89.58, for a total transaction of $6,230,378.58. Following the transaction, the executive vice president owned 10,133 shares of the company’s stock, valued at approximately $907,714.14. This represents a 87.28% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Larry Robbins sold 370,462 shares of the firm’s stock in a transaction dated Thursday, May 21st. The shares were sold at an average price of $93.45, for a total transaction of $34,619,673.90. Following the transaction, the director directly owned 4,824,799 shares in the company, valued at $450,877,466.55. This trade represents a 7.13% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 3,441,551 shares of company stock valued at $323,703,977 in the last quarter. 0.85% of the stock is currently owned by company insiders.

CVS Health Trading Up 1.8%

Shares of CVS Health stock opened at $105.97 on Tuesday. The company has a quick ratio of 0.66, a current ratio of 0.87 and a debt-to-equity ratio of 0.78. CVS Health Corporation has a twelve month low of $58.50 and a twelve month high of $106.40. The business has a 50-day moving average price of $97.36 and a 200-day moving average price of $84.41. The firm has a market cap of $135.21 billion, a price-to-earnings ratio of 46.68, a PEG ratio of 1.02 and a beta of 0.61.

CVS Health (NYSE:CVS) last issued its quarterly earnings data on Wednesday, May 6th. The pharmacy operator reported $2.57 EPS for the quarter, topping analysts’ consensus estimates of $2.21 by $0.36. CVS Health had a net margin of 0.72% and a return on equity of 11.88%. The business had revenue of $100.43 billion during the quarter, compared to analysts’ expectations of $94.99 billion. During the same period last year, the company posted $2.25 EPS. The business’s revenue was up 6.2% on a year-over-year basis. CVS Health has set its FY 2026 guidance at 7.300-7.500 EPS. Equities research analysts anticipate that CVS Health Corporation will post 7.44 EPS for the current fiscal year.

CVS Health Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Monday, August 3rd. Shareholders of record on Thursday, July 23rd will be paid a $0.665 dividend. The ex-dividend date is Thursday, July 23rd. This represents a $2.66 dividend on an annualized basis and a yield of 2.5%. CVS Health’s dividend payout ratio (DPR) is presently 117.18%.

Wall Street Analysts Forecast Growth

CVS has been the subject of a number of analyst reports. UBS Group increased their price target on CVS Health from $100.00 to $115.00 and gave the company a “buy” rating in a research report on Monday, June 8th. Truist Financial upped their target price on shares of CVS Health from $102.00 to $108.00 and gave the stock a “buy” rating in a report on Monday, June 1st. Wells Fargo & Company lifted their price target on CVS Health from $103.00 to $123.00 and gave the company an “overweight” rating in a research report on Monday. Sanford C. Bernstein upped their target price on shares of CVS Health from $94.00 to $106.00 and gave the stock an “outperform” rating in a research report on Tuesday, May 12th. Finally, Piper Sandler reiterated an “overweight” rating and set a $113.00 price target on shares of CVS Health in a research report on Monday, June 1st. Twenty-one equities research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $103.64.

About CVS Health

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over?the?counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in?store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk?in medical clinics and HealthHUB locations that offer expanded clinical services.